[Preliminary study on alternative half body irradiation in the treatment of hematological malignancies].
OBJECTIVE
To evaluate the curative effect of alternative half body irradiation (AHBI) in the treatment of hematological malignancies.


METHODS
Seventeen patients with hematological malignancies in complete remission received a high-dose chemotherapy, followed by a two-step AHBI on day 14 (12 approximately 22), upper (UHBI) and lower half body irradiation (LHBI) were sequentially given with each a single dose of 6 approximately 9 Gy at an interval of 23 (7 approximately 34) days. Fourteen received autologous hematopoietic stem cell transplantation (AHSCT) during the same period were chosen as control.


RESULTS
Hematopoiesis recovery was observed in all the AHBI patients. The 3-year disease free survival (DFS) rate and the AHBI-related mortality were (52.38 +/- 13.47)% and 0, respectively. The longest survival time was 1446 days with a median follow-up period of 927 (428 approximately 1446) days. The 3-year DFS for the 11 acute lymphocytic leukemia (ALL) patients was (47.73 +/- 17.55)%. By contrast, the 3-year DFS and the AHSCT-related mortality for the 14 ALL patients in the control AHSCT group were (53.88 +/- 14.08)% and 14%, respectively. There was no significant difference in 3-year DFS between AHBI and AHSCT ALL patients.


CONCLUSIONS
AHBI provides a feasible approach for hematological malignancy patients.
Institute of Haematology and Blood Diseases Hospital, Chinese Academy of Medical Science, Tianjin 300020, China.
Jia-Lin
JL
Wei
Mei
M
Wang
De-Hui
DH
Zou
Dong-Lin
DL
Yang
Rui
R
Li
Jun
J
Ning
Si-Zhou
SZ
Feng
Ming-Zhe
MZ
Han
D000293:Adolescent; D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D005260:Female; D019337:Hematologic Neoplasms / Q000188:drug therapy / Q000532:radiotherapy*; D017619:Hemibody Irradiation / Q000009:adverse effects / Q000379:methods*; D006801:Humans; D008297:Male; D008875:Middle Aged; D016896:Treatment Outcome